Video

Dr. Rizvi on the ECHELON-1 Trial Follow-Up in Hodgkin Lymphoma

Author(s):

Syed Rizvi, MD, discusses the 4-year follow-up data from the ECHELON-1 trial in Hodgkin lymphoma.

Syed Rizvi, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center, discusses the 4-year follow-up data from the ECHELON-1 trial in Hodgkin lymphoma.

The 4-year follow-up data from the ECHELON-1 trial solidified a benefit in progression-free survival with the combination of brentuximab vedotin (Adcetris) plus doxorubicin, vincristine, and dacarbazine (A+AVD) versus AVD plus bleomycin (ABVD) in PET2-positive patients with Hodgkin lymphoma, says Rizvi.

With these data, the skepticism regarding the effectiveness of the combination is not as prevalent as it once was, notes Rizvi. Nonetheless, the A+AVD regimen is not without adverse events. Common AEs with the regimen include neutropenia and febrile neutropenia. However, less lung toxicity is observed with A+AVD, concludes Rizvi.

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Shubham Pant, MD, MBBS
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD